Model-informed drug development for immune checkpoint inhibitors
10.16438/j.0513-4870.2020-1610
- VernacularTitle:模型引导下免疫检查点抑制剂的研发
- Author:
Guan-hao ZHENG
1
;
Chen-yu WANG
2
;
Zheng JIAO
2
Author Information
1. Shenzhen Hospital, Southern Medical University, Shenzhen 518000, China; Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai 200030, China
2. Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai 200030, China
- Publication Type:Research Article
- Keywords:
model-informed drug development;
modeling;
simulation;
pharmacometrics;
immune checkpoint inhibitor;
pembrolizumab
- From:
Acta Pharmaceutica Sinica
2021;56(3):734-742
- CountryChina
- Language:Chinese
-
Abstract:
With a deepening understanding of cancer treatment, immune checkpoint inhibitors are recognized widely as a novel fundamental remedy for various malignancies with effectiveness and safety. With the development of pharmacometrics, model-informed drug development (MIDD) has emerged to accelerate the process of clinical research for new drugs and improve the accuracy of decision-making in new drug research, especially for immune checkpoint inhibitors. As a typical illustration, the research development of pembrolizumab is presented in this review to highlight the application of MIDD, which may provide a reference for the development of other new antitumor drugs.
